Skip to main content

Advertisement

SpringerLink
Log in

An Ontology to Describe Small Molecule Pharmaceutical Product Development and Methodology for Optimal Activity Scheduling

  • Original Article
  • Published:
Journal of Pharmaceutical Innovation Aims and scope Submit manuscript

Abstract

Purpose

This contribution is the first example of a small molecule pharmaceutical product development ontology. This ontology allows the portfolio-wide visualization of the small molecule pharmaceutical development business as a network of decisions and activities. This ontology was built not only to digitalize, rapidly access, and gain insights from prior decision-making but also to deliver input data for dynamic resource allocation via optimal scheduling of research activities subject to resource, cost, and time constraints.

Methods

This ontology can be understood as a generic wiring diagram for small molecule product development which outlines the predecessors and successors of activities and decisions, along with needed or allowed overlap between activities. Each activity has multiple modes with direct dollars, resource consumption, and time taken to complete each mode.

Results

This generic wiring diagram was instanced for 17 portfolio assets by creating 32 specific scenarios. These scenarios were stored in an ontology as instances and served as foundational digitalized data for a host of future applications. These specific scenarios across the multiple assets served as input to the optimal resource allocation model.

Conclusion

In summary, this work describing pharmaceutical Chemistry Manufacturing and Controls (CMC) development activities and decisions is a foundational transformative project that enables full digitization of pharmaceutical CMC data, not only for optimal scheduling but also to generate heuristics on selection of research activities given development risks, a topic which has received virtually no mention in literature.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

References

  1. CDISC. https://www.cdisc.org/standards.

  2. Dali M, Stewart A, Behling RW, Raglione T, Stamato HJ, Tom JW. Optimizing knowledge creation at Bristol-Myers Squibb—a case study within pharmaceutical development. J Pharm Innov. 2015;10(1):1–12.

    Article  Google Scholar 

  3. Gene Ontology. http://geneontology.org/docs/ontology-documentation/.

  4. Remolona MFM, Conway MF, Balasubramanian S, Fan L, Feng Z, Gu T, et al. Hybrid ontology-learning materials engineering system for pharmaceutical products: multi-label entity recognition and concept detection. Comput Chem Eng. 2017;107:49–60.

    Article  CAS  Google Scholar 

  5. Suresh P, Hsu S-H, Reklaitis GV, Venkatasubramanian VJI, Research EC. OntoMODEL: ontological mathematical modeling knowledge management in pharmaceutical product development, 2: applications. 2010;49(17):7768–81.

  6. Venkatasubramanian V, Zhao C, Joglekar G, Jain A, Hailemariam L, Suresh P, et al. Ontological informatics infrastructure for pharmaceutical product development and manufacturing. 2006;30(10–12):1482–96.

  7. Sankar P, Aghila G. Design and development of chemical ontologies for reaction representation. 2006;46(6):2355–68.

  8. Takahashi L, Miyazato I, Takahashi K. Redesigning the Materials and Catalysts Database Construction Process Using Ontologies. 2018;58(9):1742–54.

  9. Papadakis E, Anantpinijwatna A, Woodley J, Gani RJP. A reaction database for small molecule pharmaceutical processes integrated with process information. 2017;5(4):58.

  10. Foundation A. https://www.allotrope.org/.

  11. Hua Wang JD, Guntz Steve, Vaidyaraman Shankarraman, Viswanath Shekhar, Gounaris Chrysanthos E. Portfolio-wide optimization of pharmaceutical R&D activities using mathematical programming. (Under Review).

  12. Pharmaceutical development, Q8 (2009).

  13. Quality risk management, Q9 (2006).

  14. Pharmaceutical quality system (2009).

  15. Development and manufacture of drug substances, Q11 (2012).

  16. Hartmann S, Briskorn D. A survey of variants and extensions of the resource-constrained project scheduling problem. J Eur J Oper Res. 2010;207(1):1–14. https://doi.org/10.1016/j.ejor.2009.11.005.

    Article  Google Scholar 

  17. Ho D. Addressing COVID-19 drug development with artificial intelligence. 2020;2(5):2000070.

  18. Benny P, Nair SK, Krishnakumar K, Dineshkumar B. Artificial intelligence in drug discovery and development.

  19. RSC’s RXNO Ontology. https://bioportal.bioontology.org/ontologies/RXNO.

Download references

Author information

Authors and Affiliations

  1. Small Molecule Design & Development, Eli Lilly and Company, Indianapolis, IN, USA

    Shekhar Viswanath, Steve Guntz, Jon Dieringer & Shankarraman Vaidyaraman

  2. Department of Chemical Engineering, Carnegie Mellon University, Pittsburgh, PA, USA

    Hua Wang & Chrysanthos Gounaris

Authors
  1. Shekhar Viswanath
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Steve Guntz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jon Dieringer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shankarraman Vaidyaraman
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hua Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Chrysanthos Gounaris
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shekhar Viswanath.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Viswanath, S., Guntz, S., Dieringer, J. et al. An Ontology to Describe Small Molecule Pharmaceutical Product Development and Methodology for Optimal Activity Scheduling. J Pharm Innov 17, 155–169 (2022). https://doi.org/10.1007/s12247-020-09505-6

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12247-020-09505-6

Keywords

Search

Navigation